ubiquitin conjugating enzyme E2 C pseudogene 4Genealiases: []
Q-omics provides the consensus-scored UBE2CP4 profile across patient tissues and cancer cell-line models. UBE2CP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, UBE2CP4 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, UBE2CP4 RNA expression shows 7,126 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, HNSC, and BRCA as cancer lineages where UBE2CP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2CP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2CP4 survival associations across molecular data types. UBE2CP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2CP4 RNA expression–survival associations across cancer types. High UBE2CP4 expression shows unfavorable associations in UVM, ACC, KICH, THCA and LUAD, but favorable associations in LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for UBE2CP4 RNA expression.
This table summarizes UBE2CP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2CP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2CP4 shows higher tumor expression in HNSC, UCEC, COAD, STAD and KIRC. The HNSC box plot shows higher UBE2CP4 RNA expression in tumor versus normal tissue (log2 FC = +0.062, t-test p = .001).
This table shows molecular features associated with UBE2CP4 in patient tissues and cancer cell lines. In patient samples, UBE2CP4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
